AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the
“Company”), a national provider of premium body contouring
procedures, today announced results for the third quarter and nine
months ended September 30, 2024.
“Our revenue and Adjusted EBITDA for the quarter
were in line with our expectations with the period including
progress on our strategy despite continued challenges in the
consumer environment,” said Dennis Dean, Interim Chief Executive
Officer and Chief Financial Officer of AirSculpt Technologies, Inc.
“We are pleased with our four new center openings during the
quarter and our 2023 de novo class continues to surpass our
expectations. While our same center sales remain down, we are
focused on improving the conversion of leads to consults and cases
and believe this, combined with our new center openings and our
cost reduction efforts, has us on the right track to return to
positive revenue growth while also improving our margins over
time.”
Third Quarter 2024 Results
- Case volume was 3,277 for the third
quarter of 2024, representing a 4.3% decline from the fiscal year
2023 third quarter case volume of 3,426;
- Revenue declined 9.1% to $42.5
million from $46.8 million in the fiscal 2023 third quarter;
- Net loss for the quarter was $6.0
million compared to net loss of $1.7 million in the fiscal 2023
third quarter; and
- Adjusted EBITDA was $4.7 million
compared to $9.1 million for the fiscal 2023 third quarter.
First Nine Months 2024
Results
- Case volume was 10,972, a decline
of 2.5% from the first nine months of fiscal 2023 case volume of
11,252;
- Revenue declined 4.8% to $141.2
million from $148.3 million in the first nine months of fiscal
2023;
- Net loss was $3.2 million compared
to net income of $0.1 million in the prior year period; and
- Adjusted EBITDA was $18.9 million
compared to $33.1 million for the prior year period.
2024 Outlook
The Company affirms the guidance provided on October 24, 2024
for revenue in the range of $183 million to $189 million as
compared to its previous guidance provided with second quarter
fiscal 2024 earnings of revenue in the range of $180 million to
$190 million. The Company is also maintaining its full year 2024
adjusted EBITDA guidance as follows:
- Adjusted EBITDA of approximately $23 to $28 million
- Adjusted EBITDA to cash flow from operations conversion ratio
of approximately 50% (1)
- Five new centers to open in 2024
For additional information on forward-looking statements, see
the section titled "Forward-Looking Statements" below.
(1) Calculated as cash flow from operating activities divided by
Adjusted EBITDA.
Liquidity
As of September 30, 2024, the Company had
$6.0 million in cash and cash equivalents and $5.0 million of
borrowing capacity under its revolving credit facility. The Company
generated $8.6 million in operating cash flow for the nine months
ended September 30, 2024, compared to $19.1 million for the
same period of 2023.
Conference Call Information
AirSculpt will hold a conference call today,
November 8, 2024 at 8:00 am (Eastern Time). The conference
call can be accessed by dialing 1-877-407-9716 (toll-free domestic)
or 1-201-493-6779 (international) using the conference ID 13749064
or by visiting the link below to request a return call for instant
telephone access to the event.
https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6
The live webcast may be accessed via the
investor relations section of the AirSculpt Technologies website at
https://investors.airsculpt.com. A replay of the webcast will be
available for approximately 90 days following the call.
To learn more about AirSculpt Technologies,
please visit the Company's website at
https://investors.airsculpt.com. AirSculpt Technologies uses its
website as a channel of distribution for material Company
information. Financial and other material information regarding
AirSculpt Technologies is routinely posted on the Company's website
and is readily accessible.
About AirSculpt
AirSculpt is a next-generation body contouring
treatment designed to optimize both comfort and precision,
available exclusively at AirSculpt offices. The minimally invasive
procedure removes fat and tightens skin, while sculpting targeted
areas of the body, allowing for quick healing with minimal
bruising, tighter skin, and precise results.
Forward-Looking Statements
This press release contains forward-looking
statements. In some cases, you can identify these statements by
forward-looking words such as “may,” “might,” “will,” “should,”
“expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential” or “continue,” the negative of these terms
and other comparable terminology, but the absence of these words
does not mean that a statement is not forward-looking. These
forward-looking statements, which are subject to risks,
uncertainties, and assumptions about us, may include projections of
our future financial performance, our anticipated growth
strategies, and anticipated trends in our business. These
statements are only predictions based on our current expectations
and projections about future events. You are cautioned that there
are important risks and uncertainties, many of which are beyond our
control, that could cause our actual results, level of activity,
performance, or achievements to differ materially from the
projected results, level of activity, performance or achievements
that are expressed or implied by such forward-looking statements.
We qualify all of our forward-looking statements by these
cautionary statements, including those factors discussed in the
section titled “Risk Factors” in our Annual Report on Form
10-K.
Our future results could be affected by a
variety of other factors, including, but not limited to, failure to
open and operate new centers in a timely and cost-effective manner;
inability to open new centers due to rising interest rates and
increased operating expenses due to rising inflation; increased
competition in the weight loss and obesity solutions market,
including as a result of the recent regulatory approval, increased
market acceptance, availability and customer awareness of
weight-loss drugs; shortages or quality control issues with
third-party manufacturers or suppliers; competition for surgeons;
litigation or medical malpractice claims; inability to protect the
confidentiality of our proprietary information; changes in the laws
governing the corporate practice of medicine or fee-splitting;
changes in the regulatory, macroeconomic conditions, including
inflation and the threat of recession, economic and other
conditions of the states and jurisdictions where our facilities are
located; and business disruption or other losses from war,
pandemic, terrorist acts or political unrest.
The risk factors discussed in “Item 1A. Risk
Factors” in our Annual Report on Form 10-K and in other filings we
make from time to time with the U.S. Securities and Exchange
Commission could cause our results to differ materially from those
expressed in the forward-looking statements made in this press
release.
There also may be other risks and uncertainties
that are currently unknown to us or that we are unable to predict
at this time.
Although we believe the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee future results, level of activity, performance, or
achievements. Moreover, neither we nor any other person assumes
responsibility for the accuracy and completeness of any of these
forward-looking statements. Forward-looking statements represent
our estimates and assumptions only as of the date they were made,
which are inherently subject to change, and we are under no duty
and we assume no obligation to update any of these forward-looking
statements, or to update the reasons actual results could differ
materially from those anticipated after the date of this press
release to conform our prior statements to actual results or
revised expectations, except as required by law. Given these
uncertainties, investors should not place undue reliance on these
forward-looking statements.
Use of Non-GAAP Financial Measures
The Company reports financial results in
accordance with generally accepted accounting principles in the
United States (“GAAP”), however, the Company believes the
evaluation of ongoing operating results may be enhanced by a
presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted
Net Income and Adjusted Net Income per Share, which are non-GAAP
financial measures. Although the Company provides guidance for
Adjusted EBITDA, it is not able to provide guidance for net income,
the most directly comparable GAAP measure. Certain elements of the
composition of net income, including equity-based compensation, are
not predictable, making it impractical for us to provide guidance
on net income or to reconcile our Adjusted EBITDA guidance to net
income without unreasonable efforts. For the same reasons, the
Company is unable to address the probable significance of the
unavailable information regarding net income, which could be
material to future results.
These non-GAAP financial measures are not
intended to replace financial performance measures determined in
accordance with GAAP. Rather, they are presented as supplemental
measures of the Company's performance that management believes may
enhance the evaluation of the Company's ongoing operating results.
These non-GAAP financial measures are not presented in accordance
with GAAP, and the Company’s computation of these non-GAAP
financial measures may vary from similar measures used by other
companies. These measures have limitations as an analytical tool
and should not be considered in isolation or as a substitute or
alternative to revenue, net income, operating income, cash flows
from operating activities, total indebtedness or any other measures
of operating performance, liquidity or indebtedness derived in
accordance with GAAP.
AirSculpt Technologies, Inc. and
SubsidiariesSelected Consolidated Financial
Data (Dollars in thousands, except shares and per
share amounts) |
|
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue |
$ |
42,548 |
|
|
$ |
46,793 |
|
|
$ |
141,172 |
|
|
$ |
148,309 |
|
Operating expenses: |
|
|
|
|
|
|
|
Cost of service |
|
17,766 |
|
|
|
18,175 |
|
|
|
54,635 |
|
|
|
56,144 |
|
Selling, general and administrative(1) |
|
25,495 |
|
|
|
25,030 |
|
|
|
75,525 |
|
|
|
76,805 |
|
Depreciation and amortization |
|
3,003 |
|
|
|
2,629 |
|
|
|
8,693 |
|
|
|
7,479 |
|
Loss/(gain) on disposal of long-lived assets |
|
— |
|
|
|
4 |
|
|
|
4 |
|
|
|
(198 |
) |
Total operating expenses |
|
46,264 |
|
|
|
45,838 |
|
|
|
138,857 |
|
|
|
140,230 |
|
(Loss)/income from operations |
|
(3,716 |
) |
|
|
955 |
|
|
|
2,315 |
|
|
|
8,079 |
|
Interest expense, net |
|
1,591 |
|
|
|
1,836 |
|
|
|
4,638 |
|
|
|
5,462 |
|
Pre-tax net (loss)/income |
|
(5,307 |
) |
|
|
(881 |
) |
|
|
(2,323 |
) |
|
|
2,617 |
|
Income tax expense |
|
733 |
|
|
|
786 |
|
|
|
894 |
|
|
|
2,522 |
|
Net (loss)/income |
$ |
(6,040 |
) |
|
$ |
(1,667 |
) |
|
$ |
(3,217 |
) |
|
$ |
95 |
|
|
|
|
|
|
|
|
|
(Loss)/income per share of
common stock |
|
|
|
|
|
|
|
Basic |
$ |
(0.10 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.06 |
) |
|
$ |
0.00 |
|
Diluted |
$ |
(0.10 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.06 |
) |
|
$ |
0.00 |
|
Weighted average shares
outstanding |
|
|
|
|
|
|
|
Basic |
|
57,650,923 |
|
|
|
56,785,087 |
|
|
|
57,543,678 |
|
|
|
56,661,903 |
|
Diluted |
|
57,650,923 |
|
|
|
56,785,087 |
|
|
|
57,543,678 |
|
|
|
58,329,685 |
|
(1) |
During the first quarter of fiscal year 2024, the Company recorded
a cumulative reversal of stock compensation expense of $10.4
million related to reassessing the probability of achieving the
performance target on certain of the Company's performance-based
stock units. For further discussion, see Note 6 to the condensed
consolidated financial statements of the Company's Quarterly Report
on Form 10-Q for the Quarterly Period ended September 30,
2024. |
AirSculpt
Technologies, Inc. and SubsidiariesSelected
Financial and Operating Data(Dollars in thousands,
except per case amounts) |
|
|
September 30,2024 |
|
December 31,2023 |
Balance Sheet Data (at period end): |
|
|
|
Cash and cash
equivalents |
$ |
5,972 |
|
|
$ |
10,262 |
|
Total current assets |
|
12,892 |
|
|
|
15,961 |
|
Total assets |
$ |
208,245 |
|
|
$ |
204,019 |
|
|
|
|
|
Current portion of long-term debt |
$ |
3,719 |
|
|
$ |
2,125 |
|
Deferred revenue and patient deposits |
|
2,343 |
|
|
|
1,463 |
|
Total current liabilities |
|
25,347 |
|
|
|
20,315 |
|
Long-term debt, net |
|
66,423 |
|
|
|
69,503 |
|
Total liabilities |
$ |
125,708 |
|
|
$ |
120,027 |
|
|
|
|
|
Total stockholders’ equity |
$ |
82,537 |
|
|
$ |
83,992 |
|
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Cash Flow
Data: |
|
|
|
|
|
|
|
Net cash provided by (used
in): |
|
|
|
|
|
|
|
Operating activities |
$ |
1,830 |
|
|
$ |
635 |
|
|
$ |
8,637 |
|
|
$ |
19,090 |
|
Investing activities |
|
(4,899 |
) |
|
|
(2,116 |
) |
|
|
(10,479 |
) |
|
|
(8,092 |
) |
Financing activities |
|
(825 |
) |
|
|
(10,638 |
) |
|
|
(2,448 |
) |
|
|
(11,954 |
) |
|
Three Months
EndedSeptember 30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Other Data: |
|
|
|
|
|
|
|
Number of facilities |
|
31 |
|
|
|
27 |
|
|
|
31 |
|
|
|
27 |
|
Number of total procedure rooms |
|
65 |
|
|
|
57 |
|
|
|
65 |
|
|
|
57 |
|
|
|
|
|
|
|
|
|
Cases |
|
3,277 |
|
|
|
3,426 |
|
|
|
10,972 |
|
|
|
11,252 |
|
Revenue per case |
$ |
12,984 |
|
|
$ |
13,658 |
|
|
$ |
12,867 |
|
|
$ |
13,181 |
|
Adjusted EBITDA (1) (3) |
$ |
4,666 |
|
|
$ |
9,075 |
|
|
$ |
18,871 |
|
|
$ |
33,143 |
|
Adjusted EBITDA margin (2) |
|
11.0 |
% |
|
|
19.4 |
% |
|
|
13.4 |
% |
|
|
22.3 |
% |
(1) A reconciliation of this
non-GAAP financial measure appears below. |
(2) Defined as Adjusted EBITDA
as a percentage of revenue. |
(3) For the three months
ended September 30, 2024 and 2023, pre-opening de novo and
relocation costs were $0.7 million and $0.5 million, respectively.
For the nine months ended September 30, 2024 and 2023,
pre-opening de novo and relocation costs were $0.8 million and $3.3
million, respectively. |
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Same-center
Information(1): |
|
|
|
|
|
|
|
Cases |
|
3,147 |
|
|
|
3,426 |
|
|
|
10,013 |
|
|
|
11,252 |
|
Case growth |
|
(8.1) % |
|
|
|
N/A |
|
|
|
(11.0) % |
|
|
N/A |
|
Revenue per case |
$ |
12,949 |
|
|
$ |
13,658 |
|
|
$ |
12,805 |
|
|
$ |
13,181 |
|
Revenue per case growth |
|
(5.2) % |
|
|
|
N/A |
|
|
|
(2.9) % |
|
|
N/A |
|
Number of facilities |
|
27 |
|
|
|
27 |
|
|
|
27 |
|
|
|
27 |
|
Number of total procedure
rooms |
|
57 |
|
|
|
57 |
|
|
|
57 |
|
|
|
57 |
|
(1) |
For the three months ended September 30, 2024 and 2023,
we define same-center case and revenue growth as the growth in each
of our cases and revenue at facilities that were owned and operated
during the three month period ended September 30, 2024 and
2023, respectively. At facilities that were not owned or operated
for the entirety of the prior year period, the current year period
has been pro-rated to reflect only growth experienced during the
portion of the three months ended September 30, 2024 in which
such facilities were owned and operated during the three months
ended September 30, 2023. We define same-center facilities and
procedure rooms based on if a facility was owned or operated as of
September 30, 2023. |
|
|
|
For the nine months ended September 30, 2024 and 2023, we
define same-center case and revenue growth as the growth in each of
our cases and revenue at facilities that were owned and operated
during the nine month period ended September 30, 2024 and
2023, respectively. At facilities that were not owned or operated
for the entirety of the prior year period, the current year period
has been pro-rated to reflect only growth experienced during the
portion of the nine months ended September 30, 2024 in which
such facilities were owned and operated during the nine months
ended September 30, 2023. We define same-center facilities and
procedure rooms based on if a facility was owned or operated as of
September 30, 2023. |
AirSculpt Technologies, Inc. and
SubsidiariesReconciliation of Non-GAAP Financial
Measures(Dollars in thousands)
We report our financial results in accordance
with GAAP, however, management believes the evaluation of our
ongoing operating results may be enhanced by a presentation of
Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and
Adjusted Net Income per Share, which are non-GAAP financial
measures.
We define Adjusted EBITDA as net (loss)/income
excluding depreciation and amortization, net interest expense,
income tax expense, restructuring and related severance costs,
loss/(gain) on disposal of long-lived assets, settlement costs for
non-recurring litigation, and equity-based compensation.
We define Adjusted Net Income as net
(loss)/income excluding restructuring and related severance costs,
loss/(gain) on disposal of long-lived assets, settlement costs for
non-recurring litigation, equity-based compensation and the tax
effect of these adjustments.
We include Adjusted EBITDA and Adjusted Net
Income because they are important measures on which our management
assesses and believes investors should assess our operating
performance. We consider Adjusted EBITDA and Adjusted Net Income
each to be an important measure because they help illustrate
underlying trends in our business and our historical operating
performance on a more consistent basis. Adjusted EBITDA has
limitations as an analytical tool including: (i) Adjusted
EBITDA does not include results from equity-based compensation and
(ii) Adjusted EBITDA does not reflect interest expense on our
debt or the cash requirements necessary to service interest or
principal payments. Adjusted Net Income has limitations as an
analytical tool because it does not include results from
equity-based compensation.
We define Adjusted EBITDA Margin as Adjusted
EBITDA as a percentage of revenue. We define Adjusted Net Income
per Share as Adjusted Net Income divided by weighted average basic
and diluted shares. We included Adjusted EBITDA Margin and Adjusted
Net Income per Share because they are important measures on which
our management assesses and believes investors should assess our
operating performance. We consider Adjusted EBITDA Margin and
Adjusted Net Income per Share to be important measures because they
help illustrate underlying trends in our business and our
historical operating performance on a more consistent basis.
The following table reconciles Adjusted EBITDA
and Adjusted EBITDA Margin to net (loss)/income, the most directly
comparable GAAP financial measure:
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net (loss)/income |
$ |
(6,040 |
) |
|
$ |
(1,667 |
) |
|
$ |
(3,217 |
) |
|
$ |
95 |
|
Plus |
|
|
|
|
|
|
|
Equity-based compensation(1) |
|
3,430 |
|
|
|
4,492 |
|
|
|
1,522 |
|
|
|
13,483 |
|
Restructuring and related severance costs |
|
1,099 |
|
|
|
995 |
|
|
|
5,487 |
|
|
|
4,300 |
|
Depreciation and amortization |
|
3,003 |
|
|
|
2,629 |
|
|
|
8,693 |
|
|
|
7,479 |
|
Loss/(gain) on disposal of long-lived assets |
|
— |
|
|
|
4 |
|
|
|
4 |
|
|
|
(198 |
) |
Litigation settlements(2) |
|
850 |
|
|
|
— |
|
|
|
850 |
|
|
|
— |
|
Interest expense, net |
|
1,591 |
|
|
|
1,836 |
|
|
|
4,638 |
|
|
|
5,462 |
|
Income tax expense |
|
733 |
|
|
|
786 |
|
|
|
894 |
|
|
|
2,522 |
|
Adjusted EBITDA |
$ |
4,666 |
|
|
$ |
9,075 |
|
|
$ |
18,871 |
|
|
$ |
33,143 |
|
Adjusted EBITDA Margin |
|
11.0 |
% |
|
|
19.4 |
% |
|
|
13.4 |
% |
|
|
22.3 |
% |
(1) |
As of the nine months ended September 30, 2024, this amount
contains a cumulative reversal of stock compensation expense of
$10.4 million related to reassessing the probability of achieving
the performance target on certain of the Company's
performance-based stock units. For further discussion, see Note 6
to the condensed consolidated financial statements of the Company's
Quarterly Report on Form 10-Q for the Quarterly Period ended
September 30, 2024. |
(2) |
This amount relates to settlement costs for non-recurring
litigation of $0.9 million for the three and nine months ended
September 30, 2024. This amount is accrued in "Accrued and
other current liabilities" as of September 30, 2024. See Note
9 to the condensed consolidated financial statements included in
this Quarterly Report on Form 10-Q for further discussion. |
For the three months ended
September 30, 2024 and 2023, pre-opening de novo and
relocation costs were $0.7 million and $0.5 million, respectively.
For the six months ended September 30, 2024 and 2023,
pre-opening de novo and relocation costs were $0.8 million and $3.3
million, respectively.
The following table reconciles Adjusted Net
Income and Adjusted Net Income per Share to net income/(loss), the
most directly comparable GAAP financial measure:
|
Three Months EndedSeptember
30, |
|
Nine Months EndedSeptember
30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net
(loss)/income |
$ |
(6,040 |
) |
|
$ |
(1,667 |
) |
|
$ |
(3,217 |
) |
|
$ |
95 |
|
Plus |
|
|
|
|
|
|
|
Equity-based compensation(1) |
|
3,430 |
|
|
|
4,492 |
|
|
|
1,522 |
|
|
|
13,483 |
|
Restructuring and related severance costs |
|
1,099 |
|
|
|
995 |
|
|
|
5,487 |
|
|
|
4,300 |
|
Loss/(gain) on disposal of long-lived assets |
|
— |
|
|
|
4 |
|
|
|
4 |
|
|
|
(198 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation settlements(2) |
|
850 |
|
|
|
— |
|
|
|
850 |
|
|
|
— |
|
Tax effect of adjustments |
|
(717 |
) |
|
|
(751 |
) |
|
|
996 |
|
|
|
(2,079 |
) |
Adjusted net
(loss)/income |
$ |
(1,378 |
) |
|
$ |
3,073 |
|
|
$ |
5,642 |
|
|
$ |
15,601 |
|
|
|
|
|
|
|
|
|
Adjusted net (loss)/income per
share of common stock (3) |
|
|
|
|
|
|
|
Basic |
$ |
(0.02 |
) |
|
$ |
0.05 |
|
|
$ |
0.10 |
|
|
$ |
0.28 |
|
Diluted |
$ |
(0.02 |
) |
|
$ |
0.05 |
|
|
$ |
0.10 |
|
|
$ |
0.27 |
|
Weighted average shares
outstanding |
|
|
|
|
|
|
|
Basic |
|
57,650,923 |
|
|
|
56,785,087 |
|
|
|
57,543,678 |
|
|
|
56,661,903 |
|
Diluted |
|
57,650,923 |
|
|
|
58,954,829 |
|
|
|
58,289,022 |
|
|
|
58,329,685 |
|
(1) |
During the first quarter of fiscal year 2024, the Company recorded
a cumulative reversal of stock compensation expense of $10.4
million related to reassessing the probability of achieving the
performance target on certain of the Company's performance-based
stock units. For further discussion, see Note 6 to the condensed
consolidated financial statements of the Company's Quarterly Report
on Form 10-Q for the Quarterly Period ended September 30,
2024. |
(2) |
This amount relates to settlement costs for non-recurring
litigation of $0.9 million for the three and nine months ended
September 30, 2024. This amount is accrued in "Accrued and
other current liabilities" as of September 30, 2024. See Note
9 to the condensed consolidated financial statements included in
this Quarterly Report on Form 10-Q for further discussion. |
(3) |
Diluted Adjusted Net Income Per Share is computed by dividing
adjusted net income by the weighted-average number of shares of
common stock outstanding adjusted for the dilutive effect of all
potential shares of common stock. |
Investor ContactAllison MalkinICR,
Inc.airsculpt@icrinc.com
AirSculpt Technologies (NASDAQ:AIRS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
AirSculpt Technologies (NASDAQ:AIRS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024